Abstract:Muhammad Asad Faruqi, 1 Malik M Khurram S Khan, 1 David M Mannino 1, 2 1 University of Kentucky College of Medicine, Lexington, KY, USA; 2 COPD Foundation, Miami, FL, USA Correspondence: David M Mannino, Department of Medicine, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY, 40536, USA, Email Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder of the respiratory system which is characterized by irreversible airflow obstruction, remodeling of the airways and acute exacerbations leading to lung function decline, progressive dyspnea, and cough. 1 Treatment of COPD is aimed towards reducing symptoms like shortness of breath and mucous production, preventing flare-ups, slowing disease progression and improving survival. COPD therapies involve both non-pharmacological and pharmacological interventions. Some patients on maximal therapies, including inhaled bronchodilators and steroids and oral phosphodiesterase 4 (PDE4) inhibitors, can still be symptomatic. Thus, new therapies are needed that can improve lung function and airway inflammation when used in addition to existing therapies. 2,3 In addition, current inhaled therapies may not be tolerated by all patients. Thus, therapies with alternative mechanisms of action are needed. In this article, we review the literature available on ensifentrine, a novel phosphodiesterase inhibitor that has the potential to be an add-on therapy for patients with COPD. Ensifentrine (RPL554) is a novel drug that works by dual inhibition of phosphodiesterase (PDE) 3 and 4 enzymes (PDE3, PDE4) and is designed to be delivered via inhalation. 4 Inhibitors of PDE3 and PDE4 target multiple respiratory functions at the cellular and tissue level (Figure 1). PDE3 regulates cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the airway smooth muscles, which mediates bronchial tone. 5 PDE4 regulates cAMP levels in the airway cells associated with inflammation and is involved in activation of these cells. 6 PDE4 inhibitors can also activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and improve bronchial epithelial cell ciliary movements. 7 Evidence has recently emerged that dual inhibition of PDE3 and PDE4 enzymes results in a synergistic effect of decreased inflammation and improved bronchodilation as both iso-forms of PDE are expressed in the inflammatory cells and airway smooth muscles. 8,9 This article explores the evidence to date regarding ensifentrine as a novel therapeutic option for the treatment of COPD. Figure 1 Combined inhibition of phosphodiesterase (PDE) 3 and PDE4 has additive and synergistic anti-inflammatory and bronchodilatory effects versus inhibition of either PDE3 or PDE4 alone. Furthermore, it increases mucociliary clearance. In red, the main PDE involved in the activity of the specific cell. With permission, from Current Opinion in Pharmacology. Notes : Reprinted from Current Opinion in Pharmacology, Volume 56, Matera MG, Cazzola M, Page C, Prospects for COPD treatment. pages 74–84, copyright 2021, with permission from Elsevier. 3 Several in vitro and in vivo studies evaluated the effect of PDE3/4 inhibitors on airway smooth muscles and degree of inflammation. One study investigated the effects of ensifentrine (RPL554) on the tone of isolated human airway smooth muscles and its synergistic actions when used in conjunction with other bronchodilators including muscarinic antagonists and beta-adrenergic agonists. The study demonstrated that ensifentrine caused relaxation of the bronchial smooth muscles and had a synergistic effect when used with muscarinic antagonists. 10 Ensifentrine's effect on bronchial epithelial cell cultures obtained from normal and Cystic Fibrosis (CF) patients with F508del genotype has also been evaluated. 11 It stimulates CFTR-dependent chloride ion secretion across bronchial epithelial cells and increases cilia beat frequency in primary human bronchial epithelial cells. It also decreases the production of monocyte chemoattractant protein-1 and granulocyte monocyte colony -Abstract Truncated-

Ensifentrine (OhtuvayreTM) for chronic obstructive pulmonary disease

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Ensifentrine: First Approval

What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials

Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials

The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement

Molecular hybridization yields triazole bronchodilators for the treatment of COPD

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione

Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors

Exploring theophylline-1,2,4-triazole tethered N-phenylacetamide derivatives as antimicrobial agents: unraveling mechanisms via structure-activity relationship, in vitro validation, and in silico insights

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

One-pot synthesis and pharmacological evaluation of new quinoline/pyrimido-diazepines as pulmonary antifibrotic agents

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension

"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher. Eur Respir Rev 2023; 32: 220206.

Fungerps: discovery of the glucan synthase inhibitor enfumafungin and development of a new class of antifungal triterpene glycosides

GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket